AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00633399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: 20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
Study NCT00633399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo.
Study NCT01960569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active product ( Thrombexx) assigned to arm 1
Description: Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
Study NCT01960569 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo assigned to arm 2
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg dose, orally administered
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: 200mg dose
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: 600mg dose
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Description: 600mg tablets
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 1mg dose
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolbutamide
Description: 500mg dose
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2mg dose
Study NCT03723395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: 0.5 mg dose
Study NCT01458002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Internet Communication with Relational Agent
Description: The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site.
Study NCT01458002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tailored Internet Communication with Relational Agent
Description: The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site.
Study NCT01458002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tailored Internet Communications
Description: Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
Study NCT01050088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose solution
Description: 5cc 5% sucrose solution P/O
Study NCT01050088 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5cc saline p/o
Study NCT00987948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc (Selzentry)
Description: dosage varies with other medications being taken; will follow package insert guidelines
Study NCT01496183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
Study NCT01496183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule administered orally at bedtime for 14 days
Study NCT02170506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urostim 2 stimulation
Description: Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
Study NCT02867280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: red round tablet
Study NCT01146483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin, Pantoprazole
Description: Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
Study NCT02458417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCell
Description: A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
Study NCT02458417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReCell
Description: A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
Study NCT02458417 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full surface CO2 laser 200 mJ
Description: Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
Study NCT02458417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full surface CO2 laser 150 mJ
Description: Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
Study NCT02458417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser 7.5 mJ, 20%
Description: Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 200 mg
Description: 1 X 200-mg tablet taken orally
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets taken orally
Study NCT02226341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept
Description: For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273-400 mg
Description: 2 X 200-mg tablet taken orally
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 tablet taken orally
Study NCT02226341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTHar gel
Description: Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.~Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
Study NCT00376961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 on day 1 for cycles 1-6.
Study NCT00376961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273-600 mg
Description: 3 X 200-mg tablet taken orally
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 tablets taken orally
Study NCT04024137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo of ZSP1273
Study NCT02214810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/Exparel
Description: The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
Study NCT02214810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine/Exparel
Description: The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
Study NCT03698461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: * 1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~* 840mg IV D1 of C1-12 (Cycle: every 2 weeks)
Study NCT00376961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m\^2 on day 1 of cycles 1-6.
Study NCT00376961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/m\^2 on day 1 of cycles 1-6.
Study NCT03698461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
Study NCT03698461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
Study NCT00376961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on days 1-5 of cycles 1-6.
Study NCT00376961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m\^2 on day 1 of cycles 1-6.
Study NCT05237557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative nurse dialogue
Description: Performance of a preoperative nurse dialogue prior major visceral surgery
Study NCT04920409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAWGT diet
Description: Composed of 15% protein, 55% CH and 30% fat of which \< 10% was SFA, 14% MUFA and 6% PUFA in the overall total caloric content.
Study NCT04920409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet (UD)
Description: Consisted of 16% protein, 54% carbohydrates (CH) and 30% fat of which 15% was saturated fat (SFA), 10% monounsaturated fat (MUFA) and 5% polyunsaturated fat (PUFA)in relation to the total caloric content
Study NCT03698461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin
Description: 200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
Study NCT03698461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: * 5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~* 5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)
Study NCT00618722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Study NCT00618722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01925989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered SQ
Study NCT01925989 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SQ
Study NCT02842905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fitting Audiologist completion
Description: Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
Study NCT02842905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant's Physician completion
Description: Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
Study NCT03726996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Description: Study drug (desipramine) provided in tablet form to be taken daily.
Study NCT02012582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAS203
Description: i.v. infusion
Study NCT02243384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Hepatectomy
Description: A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
Study NCT02243384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
Study NCT02012582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: i.v. infusion
Study NCT04964193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elzsa film-coated tablet
Description: Administered with 240 mL of water
Study NCT04964193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane-35 Sugar-coated tablet
Description: Administered with 240 mL of water
Study NCT03513081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educative session
Description: The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
Study NCT00511225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: 10,000 IU weekly
Study NCT00511225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule
Study NCT00865423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg Tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Study NCT00865423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 800 mg Tablets, single dose
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Study NCT01676038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pinless-Navigated Total Knee Arthroplasty
Description: Brainlab VectorVision Knee 2.5 Navigation System
Study NCT01676038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Total Knee Arthroplasty
Description: Conventional technique.
Study NCT04387292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmologic exam
Description: * Visual acuity (ETDRS exam)~* Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test~* Lipiview~* Eye pressure measurement (air tonometer)~* Wide field retinophotography~* Multicolor and auto-fluorescence retinophotography~* Indocyanine green retinal angiography~* Optical coherence tomography (OCT) B posterior pole scan~* OCT Angiography (OCT-A) of the optic nerve and posterior pole~* Adaptive optics~* Visual field (Humphrey)
Study NCT00482963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel, efavirenz
Study NCT03551548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg
Description: 25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
Study NCT03551548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
Study NCT01136551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huperzine A
Description: Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
Study NCT01136551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A
Description: Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
Study NCT01401569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and counseling (for smoking cessation and physical activity)
Description: Exercise and counseling (for smoking cessation and physical activity)
Study NCT01401569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and counseling (for smoking cessation and physical activity)
Description: Exercise and counseling (for smoking cessation and physical activity)
Study NCT02312024 — intervention group
Intervention type: DEVICE
Intervention: Use of CytoSorb adsorber
Description: Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
Study NCT04239846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-701 Topical Gel 0.3%
Description: AC-701 Topical Gel 0.3%, BID
Study NCT04239846 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel, BID
Study NCT03700411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine intravenous
Study NCT03700411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Piritramid intravenous
Study NCT03700411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Perioperative epidural analgesia
Study NCT02692547 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hybrid-logic closed loop system
Description: All patients get to wear the pump
Study NCT02684071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra thecal methotrexate
Description: IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
Study NCT02684071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: To be administered in conjunction with methotrexate
Study NCT02684071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: To be administered in conjunction with methotrexate and topotecan
Study NCT01417676 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: pelvic lymph nodes with boost to prostate
Description: 78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
Study NCT01332708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high complex carbohydrates diet given in a diet group
Description: diet groups that meet every week for eight weeks or more.
Study NCT00709826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine: per package insert.